Internal Medicine, Rheumatology · Sewell, NJ
NPI
1174786297
Since 2008
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
123 Egg Harbor Rd, Suite 804
Sewell, NJ, 08080
Phone (856) 302-0500
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
200,202 services
Medicare patients, 2024
911
Average age 73
Drug cost, 2024
$6.9M
6,834 prescriptions
Company payments, 2025
$1,443
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vijay Singh was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 121,200 times for 44 patients. In total Vijay Singh billed 200,202 services in 35 codes, and Medicare paid $1.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 121,200 | 44 | $3.54 | $429K |
| J0897 Injection, denosumab, 1 mg | Office | 20,940 | 218 | $20.35 | $426K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 19,140 | 111 | $0.09 | $1,803 |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 13,375 | 30 | $33.71 | $451K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,484 | 12 | $8.93 | $94K |
| 99214 Office E&M - Established | Office | 1,987 | 803 | $94.42 | $188K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,203 | 592 | $13.03 | $16K |
| 96401 Chemotherapy Administration | Office | 1,018 | 284 | $60.38 | $61K |
| 96413 Chemotherapy Administration | Office | 437 | 86 | $107.86 | $47K |
| 20610 Joint Injection | Office | 265 | 114 | $62.19 | $16K |
| 99215 Office E&M - Established | Office | 219 | 139 | $129.23 | $28K |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 172 | 50 | $4.43 | $763 |
| 96415 Chemotherapy Administration | Office | 103 | 19 | $23.10 | $2,379 |
| 99204 Office E&M - New | Office | 98 | 98 | $126.93 | $12K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 65 | 13 | $5.16 | $335 |
By year: 2022 $2.3M for 196,626 services; 2023 $1.9M for 183,451 services; 2024 $1.9M for 200,202 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vijay Singh prescribed most often to Medicare patients was Prednisone, with 900 prescriptions and refills. In total Vijay Singh wrote 6,834 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 900 | 1,953 | 309 | $9,399 |
| Gabapentin Generic | 706 | 1,629 | 249 | $13K |
| Methotrexate Methotrexate Sodium | 691 | 1,850 | 228 | $26K |
| Hydroxychloroquine Sulfate Generic | 424 | 1,167 | 134 | $28K |
| Alendronate Sodium Generic | 261 | 678 | 92 | $2,532 |
| Tramadol Hcl Generic | 257 | 259 | 64 | $1,267 |
| Prolia Denosumab | 240 | 1,389 | 157 | $428K |
| Methylprednisolone Generic | 211 | 261 | 142 | $2,277 |
| Meloxicam Generic | 198 | 485 | 79 | $1,185 |
| Benlysta Belimumab | 154 | 155 | 14 | $508K |
| Diclofenac Sodium Generic | 144 | 271 | 70 | $13K |
| Duloxetine Hcl Generic | 143 | 369 | 55 | $2,617 |
| Pilocarpine Hcl Generic | 143 | 356 | 55 | $18K |
| Allopurinol Generic | 116 | 322 | 34 | $1,369 |
| Humira(Cf) Pen Adalimumab | 114 | 133 | 16 | $920K |
Brand drugs: 1,450 claims; generic drugs: 5,366 claims; opioid claims: 299.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vijay Singh $1,443 ($1,443 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $426.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 37 | $426 |
| UCB, Inc. UCB.BR | 13 | $204 |
| Amgen Inc. AMGN | 11 | $181 |
| Janssen Biotech, Inc. JNJ | 7 | $126 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $110 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $96.66 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $52.03 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $49.04 |
| Organon LLC OGN | 3 | $37.76 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $18.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.